$Histogenics Corporation(OCGN)$

Smart financial app learned that swayampakula ramakanth, an analyst at H.C. Wainwright, published a research report, believing that the potential new crown vaccine will become ocugen（ OCGN.US ）The target price is $12, which is more than 40% higher than the current share price. Ramakanth believes the company's $47 million cash position should be enough to support its operations through 2023. Assuming regulatory approval for the new coronal vaccine covaxin from its partner Bharat biotech, the analyst expects revenue of $280 million and diluted earnings per share of $1.10 in 2021. Ocugen has signed an agreement with Bharat to introduce covaxin into the United States. The company will supervise the clinical development of the vaccine, obtain regulatory approval, and undertake all commercialization work in the United States. In return, ocugen will make a 45% profit. It is reported that covaxin has been authorized for emergency use in India, and the mid-term analysis of phase 3 clinical trials shows that its effectiveness is 81%.